Related Experiment Video
Updated: Apr 22, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Abstract:
In a phase I/II clinical trial, patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer treated with the next-generation KRASG12C inhibitor elisrasib showed robust and durable clinical responses. Patients naïve to KRASG12C inhibitors, as well as those refractory to other such drugs, experienced high rates of disease control-98.5% and 83.9%, respectively.
Insights
Elisrasib, a KRAS G12C inhibitor, demonstrated significant clinical responses in patients with non-small cell lung cancer. This next-generation drug showed high disease control rates in both treatment-naïve and previously treated patient groups.
Area of Science:
- Oncology
- Pharmacology
Background:
- KRAS G12C mutations are common drivers in non-small cell lung cancer (NSCLC).
- Targeted therapies are crucial for improving outcomes in advanced NSCLC.
Purpose of the Study:
- To evaluate the safety and efficacy of elisrasib, a novel KRAS G12C inhibitor.
- To assess clinical responses in patients with locally advanced or metastatic KRAS G12C-mutant NSCLC.
Main Methods:
- Phase I/II clinical trial.
- Treatment with elisrasib in patients with KRAS G12C-mutant NSCLC.
Main Results:
- Robust and durable clinical responses observed with elisrasib.
- High disease control rates: 98.5% in treatment-naïve patients and 83.9% in patients refractory to other KRAS G12C inhibitors.
Conclusions:
- Elisrasib shows promising efficacy in treating KRAS G12C-mutant NSCLC.
- The drug is effective in both previously untreated and pre-treated patient populations.
More Related Videos
Related Concept Videos
02:38The Ras Gene
Ras is a...
02:23Abnormal Proliferation
02:56Treatment Resistent Cancers